United Therapeutics (UTHR) Common Equity (2009 - 2026)
United Therapeutics (UTHR) posted Common Equity of $5.9 billion for Q1 2026, down 16.84% sequentially from $7.1 billion in Q4 2025, and down 13.31% YoY from $6.8 billion in Q1 2025.
United Therapeutics (UTHR) Common Equity (2009 - 2026) Analysis & Trends
United Therapeutics has reported Common Equity for 18 years, with the latest figure at $5.9 billion in Q1 2026.
- Quarterly Common Equity fell 13.31% year-over-year to $5.9 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.9 billion (down 13.31% YoY) and the FY2025 annual result came in at $7.1 billion, up 10.12% from the prior year.
- Common Equity retreated to $5.9 billion in Q1 2026 per UTHR's latest filing, from $7.1 billion in the prior quarter.
- Over five years, Common Equity peaked at $7.2 billion in Q2 2025 and troughed at $63.0 million in Q3 2024.
- A 5-year average of $5.4 billion and a median of $5.7 billion in 2024 frame the typical range for Common Equity.
- The sharpest annual moves came in 2024 and 2025: Common Equity sank 98.9% in 2024, then surged 10360.63% in 2025.
- Over 5 years, Common Equity stood at $4.8 billion in 2022, then climbed by 24.77% to $6.0 billion in 2023, then gained by 7.67% to $6.4 billion in 2024, then grew by 10.12% to $7.1 billion in 2025, then dropped by 16.84% to $5.9 billion in 2026.
- According to Business Quant data, Common Equity over the past three periods registered $5.9 billion, $7.1 billion, and $6.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.91 Bn | 42.95 Bn | - | 22.06 Bn |
| 2 | Teva Pharmaceutical Industries | 42.98 Bn | 39.32 Bn | 2.15 Bn | 7.76 Bn |
| 3 | Zoetis | 31.53 Bn | 29.86 Bn | 1.05 Bn | 3.15 Bn |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 47.42 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 6.40 Bn |
| 6 | Viatris | 18.74 Bn | 17.85 Bn | 1.46 Bn | 14.26 Bn |
| 7 | Neurocrine Biosciences | 15.51 Bn | 15.12 Bn | 935.80 Mn | 3.69 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 6.59 Bn |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | 4.05 Bn |
| 10 | Alkermes | 8.12 Bn | 7.46 Bn | 397.90 Mn | 1.81 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 6.40 Bn |
| Mar 31, 2026 | 5.90 Bn |
| Dec 31, 2025 | 7.10 Bn |
| Sep 30, 2025 | 6.59 Bn |
| Jun 30, 2025 | 7.17 Bn |
| Mar 31, 2025 | 6.81 Bn |
| Dec 31, 2024 | 6.44 Bn |
| Sep 30, 2024 | 63.00 Mn |
| Jun 30, 2024 | 5.70 Bn |
| Mar 31, 2024 | 5.34 Bn |
| Dec 31, 2023 | 5.98 Bn |
| Sep 30, 2023 | 5.71 Bn |
| Jun 30, 2023 | 5.41 Bn |
| Mar 31, 2023 | 5.12 Bn |
| Dec 31, 2022 | 4.80 Bn |
| Sep 30, 2022 | 4.56 Bn |
| Jun 30, 2022 | 4.32 Bn |
| Mar 31, 2022 | 4.18 Bn |
| Dec 31, 2021 | 3.96 Bn |
| Sep 30, 2021 | 3.83 Bn |